Cartilage That Refuses to Grow Back

Osteoarthritis (OA) destroys articular cartilage — the load-bearing tissue lining joint surfaces — but adult human cartilage has near-zero intrinsic regenerative capacity. Once cartilage is lost, it does not grow back. The only definitive treatment is total joint replacement, a major surgery with a 15–20 year prosthetic lifespan that is unsuitable for younger patients and carries significant surgical risk for the elderly. No injectable, non-invasive, or biologic therapy has demonstrated the ability to regenerate hyaline cartilage (the load-bearing type) in a damaged joint. The fundamental barrier is biological: adult chondrocytes are terminally differentiated, avascular, and embedded in dense extracellular matrix with no stem cell niche to drive repair.

OA affects over 32 million Americans and 500+ million people globally, with prevalence rising as populations age and obesity rates increase. It is the leading cause of disability in adults over 65. Annual U.S. healthcare costs exceed $136 billion, with over 1 million joint replacements performed annually. For patients too young for joint replacement (onset can begin in the 30s–40s after injury), there is no disease-modifying treatment — only pain management through NSAIDs, corticosteroid injections, and physical therapy, all of which address symptoms, not the underlying cartilage loss.

Microfracture surgery (drilling holes in bone to release marrow stem cells into the defect) produces fibrocartilage — a weaker, structurally inferior tissue that breaks down within 2–5 years. Autologous chondrocyte implantation (ACI) can repair small, focal defects but requires two surgeries, grows inconsistent tissue quality, and does not address the diffuse cartilage loss pattern of OA. Platelet-rich plasma (PRP) and hyaluronic acid injections provide temporary symptom relief but do not regenerate tissue. Mesenchymal stem cell injections showed promise in animal models but clinical trials have produced inconsistent results, likely because injected cells do not survive long enough in the hostile inflammatory joint environment to produce organized hyaline cartilage. No approach has solved the fundamental challenge: stimulating organized, load-bearing hyaline cartilage growth in a weight-bearing, mechanically stressed, inflamed environment.

Three technical advances are needed: (1) injectable biologics (growth factors, gene therapies, or engineered cells) that can stimulate endogenous cartilage repair by activating or reprogramming cells already present in the joint; (2) biomaterial scaffolds that can template organized hyaline cartilage formation in the mechanically loaded joint environment; (3) for advanced OA, biologically-derived replacement joints made from a patient's own cells that integrate with surrounding tissue and bear physiological loads — eliminating permanent hardware. Understanding why some species (salamanders, zebrafish) regenerate cartilage while mammals cannot could reveal targetable molecular pathways.

A student team could evaluate the mechanical properties of different hydrogel scaffolds under cyclic loading conditions that simulate the joint environment, testing which formulations maintain structural integrity while supporting chondrocyte viability. A computational team could analyze single-cell RNA sequencing data from OA and healthy cartilage to identify transcription factors that distinguish regeneration-competent cells from terminally differentiated chondrocytes. Relevant disciplines: biomedical engineering, biomaterials, cell biology, regenerative medicine.